4.4 Article

RegR Virulence Regulon of Rabbit-Specific Enteropathogenic Escherichia coli Strain E22

Journal

INFECTION AND IMMUNITY
Volume 81, Issue 4, Pages 1078-1089

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/IAI.01325-12

Keywords

-

Funding

  1. Australian National Health & Medical Research Council (NHMRC)
  2. NHMRC Independent Research Institutes Infrastructure Support Scheme
  3. Victorian State Government Operational Infrastructure Support Program
  4. NHMRC Peter Doherty Australian Biomedical Fellowship

Ask authors/readers for more resources

AraC-like regulators play a key role in the expression of virulence factors in enteric pathogens, such as enteropathogenic Escherichia coli (EPEC), enterotoxigenic E. coli, enteroaggregative E. coli, and Citrobacter rodentium. Bioinformatic analysis of the genome of rabbit-specific EPEC (REPEC) strain E22 (O103:H2) revealed the presence of a gene encoding an AraC-like regulatory protein, RegR, which shares 71% identity to the global virulence regulator, RegA, of C. rodentium. Microarray analysis demonstrated that RegR exerts 25- to 400-fold activation on transcription of several genes encoding putative virulence-associated factors, including a fimbrial operon (SEF14), a serine protease, and an autotransporter adhesin. These observations were confirmed by proteomic analysis of secreted and heat-extracted surface-associated proteins. The mechanism of RegR-mediated activation was investigated by using its most highly upregulated gene target, sefA. Transcriptional analyses and electrophoretic mobility shift assays showed that RegR activates the expression of sefA by binding to a region upstream of the sefA promoter, thereby relieving gene silencing by the global regulatory protein H-NS. Moreover, RegR was found to contribute significantly to virulence in a rabbit infection experiment. Taken together, our findings indicate that RegR controls the expression of a series of accessory adhesins that significantly enhance the virulence of REPEC strain E22.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Meeting Abstract Biochemistry & Molecular Biology

Prior Ablation of the Splanchnic Sympathetic Nerves Increases Plasma Inflammatory Cytokine Levels and Suppresses Bacteremia in Response to Systemically Administered E. coli in Sheep

Michael McKinley, Kaylani Almeida, Sammy Bedoui, David Farmer, Dianna Hocking, Yugeesh Lankadeva, Davide Martelli, Clive May, Roy Robins-Browne, Robin McAllen

FASEB JOURNAL (2020)

Article Immunology

Risk Factors for Carriage of Antibiotic-resistant Bacteria in Healthy Children in the Community A Systematic Review

Nicole L. Messina, Deborah A. Williamson, Roy Robins-Browne, Penelope A. Bryant, Nigel Curtis

PEDIATRIC INFECTIOUS DISEASE JOURNAL (2020)

Letter Dentistry, Oral Surgery & Medicine

Vertical transmission

A. Riad, B. Hockova

BRITISH DENTAL JOURNAL (2020)

Article Pathology

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

Eun Young Kang, Dane Cheasley, Cecile LePage, Matthew J. Wakefield, Michelle da Cunha Torres, Simone Rowley, Carolina Salazar, Zhongyue Xing, Prue Allan, David D. L. Bowtell, Anne-Marie Mes-Masson, Diane M. Provencher, Kurosh Rahimi, Linda E. Kelemen, Peter A. Fasching, Jennifer A. Doherty, Marc T. Goodman, Ellen L. Goode, Suha Deen, Paul D. P. Pharoah, James D. Brenton, Weiva Sieh, Constantina Mateoiu, Karin Sundfeldt, Linda S. Cook, Nhu D. Le, Michael S. Anglesio, C. Blake Gilks, David G. Huntsman, Catherine J. Kennedy, Nadia Traficante, Anna DeFazio, Scott Kaufmann, Michael Churchman, Charlie Gourley, Andrew N. Stephens, Nicola S. Meagher, Susan J. Ramus, Yoland C. Antill, Ian Campbell, Clare L. Scott, Martin Kobel, Kylie L. Gorringe

Summary: The study confirmed the ability of TP53 IHC to predict TP53 mutation status in ovarian mucinous tumors and showed that TP53 mutation is associated with a higher risk of mortality in MBOT patients.

MODERN PATHOLOGY (2021)

Letter Cell Biology

Primary mucinous ovarian neoplasms rarely show germ cell histogenesis

Felix K. F. Kommoss, Dane Cheasley, Matthew J. Wakefield, Clare L. Scott, Ian G. Campbell, C. Blake Gilks, Kylie Gorringe

HISTOPATHOLOGY (2021)

Article Immunology

Mycobacterium ulcerans-specific immune response after immunisation with bacillus Calmette-Guerin (BCG) vaccine

Laure F. Pittet, Marc Tebruegge, Binita Dutta, Susan Donath, Nicole Messina, Dan Casalaz, Willem A. Hanekom, Warwick J. Britton, Roy Robins-Browne, Nigel Curtis, Nicole Ritz

Summary: BCG vaccination induces M. ulcerans-specific immune responses in infants, likely explaining the cross-protective effect observed in epidemiological studies. These immune responses show similar patterns to those observed in M. tuberculosis-stimulated samples.

VACCINE (2021)

Article Cell Biology

Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors

Christoph Grohmann, Francesca Walker, Mark Devlin, Meng-Xiao Luo, Anderly C. Chueh, Judy Doherty, Francois Vaillant, Gwo-Yaw Ho, Matthew J. Wakefield, Clare E. Weeden, Alvin Kamili, Jayne Murray, Sela T. Po'uha, Janet Weinstock, Serena R. Kane, Maree C. Faux, Esmee Broekhuizen, Ye Zheng, Kristy Shield-Artin, Nadia J. Kershaw, Chin Wee Tan, Helen M. Witchard, Gregor Ebert, Susan A. Charman, Ian Street, Maria Kavallaris, Michelle Haber, Jamie I. Fletcher, Marie-Liesse Asselin-Labat, Clare L. Scott, Jane E. Visvader, Geoffrey J. Lindeman, Keith G. Watson, Antony W. Burgess, Guillaume Lessene

Summary: Targeting cell division by the new small molecule WEHI-7326 shows promising anti-tumor activity with broad-spectrum efficacy, providing a potential new therapeutic option for cancer patients.

CELL DEATH & DISEASE (2021)

Article Oncology

Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma

Ksenija Nesic, Olga Kondrashova, Rachel M. Hurley, Cordelia D. McGehee, Cassandra J. Vandenberg, Gwo-Yaw Ho, Elizabeth Lieschke, Genevieve Dall, Nirashaa Bound, Kristy Shield-Artin, Marc Radke, Ashan Musafer, Zi Qing Chai, Mohammad Reza Eftekhariyan Ghamsari, Maria Harrell, Damien Kee, Inger Olesen, Orla McNally, Nadia Traficante, Anna DeFazio, David D. L. Bowtell, Elizabeth M. Swisher, S. John Weroha, Katia Nones, Nicola Waddell, Scott H. Kaufmann, Alexander Dobrovic, Matthew J. Wakefield, Clare L. Scott

Summary: This study revealed that methylation patterns in the RAD51C promoter are closely associated with sensitivity to PARP inhibitors, with complete or heterogeneous methylation affecting drug resistance development. Additionally, genomic profiling showed that resistance to PARPi can be acquired independently in genetically distinct lineages.

CANCER RESEARCH (2021)

Article Critical Care Medicine

Bacillus Calmette-Guerin Skin Reaction Predicts Enhanced Mycobacteria-Specific T-Cell Responses in Infants A Post Hoc Analysis of a Randomized Controlled Trial

Laure F. Pittet, Nora Fritschi, Marc Tebruegge, Binita Dutta, Susan Donath, Nicole L. Messina, Dan Casalaz, Willem A. Hanekom, Warwick J. Britton, Roy Robins-Browne, Nigel Curtis, Nicole Ritz

Summary: The presence of a scar after BCG vaccination is associated with stronger mycobacteria-specific T-cell responses. Further study on the relationship between scar formation and protection against tuberculosis as well as the need for revaccination in scar-negative individuals is important.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2022)

Article Oncology

Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin

Gwo Yaw Ho, Elizabeth L. Kyran, Justin Bedo, Matthew J. Wakefield, Darren P. Ennis, Hasan B. Mirza, Cassandra J. Vandenberg, Elizabeth Lieschke, Andrew Farrell, Anthony Hadla, Ratana Lim, Genevieve Dall, James E. Vince, Ngee Kiat Chua, Olga Kondrashova, Rosanna Upstill-Goddard, Ulla-Maja Bailey, Suzanne Dowson, Patricia Roxburgh, Rosalind M. Glasspool, Gareth Bryson, Andrew V. Biankin, Susanna L. Cooke, Gayanie Ratnayake, Orla McNally, Nadia Traficante, Anna DeFazio, S. John Weroha, David D. Bowtell, Iain A. McNeish, Anthony T. Papenfuss, Clare L. Scott, Holly E. Barker

Summary: Genomic analyses and preclinical models of ovarian carcinosarcoma support the conversion theory for disease development and indicate that microtubule inhibitors could be used to suppress EMT and stimulate antitumor immunity.

CANCER RESEARCH (2022)

Article Oncology

Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

Nicola S. Meagher, Kylie L. Gorringe, Matthew Wakefield, Adelyn Bolithon, Chi Nam Ignatius Pang, Derek S. Chiu, Michael S. Anglesio, Kylie-Ann Mallitt, Jennifer A. Doherty, Holly R. Harris, Joellen M. Schildkraut, Andrew Berchuck, Kara L. Cushing-Haugen, Ksenia Chezar, Angela Chou, Adeline Tan, Jennifer Alsop, Ellen Barlow, Matthias W. Beckmann, Jessica Boros, David D. L. Bowtell, Alison H. Brand, James D. Brenton, Ian Campbell, Dane Cheasley, Joshua Cohen, Cezary Cybulski, Esther Elishaev, Ramona Erber, Rhonda Farrell, Anna Fischer, Zhuxuan Fu, Blake Gilks, Anthony J. Gill, Charlie Gourley, Marcel Grube, Paul R. Harnett, Arndt Hartmann, Anusha Hettiaratchi, Claus K. Hogdall, Tomasz Huzarski, Anna Jakubowska, Mercedes Jimenez-Linan, Catherine J. Kennedy, Byoung-Gie Kim, Jae-Weon Kim, Jae-Hoon Kim, Kayla Klett, Jennifer M. Koziak, Tiffany Lai, Angela Laslavic, Jenny Lester, Yee Leung, Na Li, Winston Liauw, Belle W. X. Lim, Anna Linder, Jan Lubinski, Sakshi Mahale, Constantina Mateoiu, Simone McInerny, Janusz Menkiszak, Parham Minoo, Suzana Mittelstadt, David Morris, Sandra Orsulic, Sang-Yoon Park, Celeste Leigh Pearce, John Pearson, Malcolm C. Pike, Carmel M. Quinn, Ganendra Raj Mohan, Jianyu Rao, Marjorie J. Riggan, Matthias Ruebner, Stuart Salfinger, Clare L. Scott, Mitul Shah, Helen Steed, Colin J. R. Stewart, Deepak Subramanian, Soseul Sung, Katrina Tang, Paul Timpson, Robyn L. Ward, Rebekka Wiedenhoefer, Heather Thorne, Paul A. Cohen, Philip Crowe, Peter A. Fasching, Jacek Gronwald, Nicholas J. Hawkins, Estrid Hogdall, David G. Huntsman, Paul A. James, Beth Y. Karlan, Linda E. Kelemen, Stefan Kommoss, Gottfried E. Konecny, Francesmary Modugno, Sue K. Park, Annette Staebler, Karin Sundfeldt, Anna H. Wu, Aline Talhouk, Paul D. P. Pharoah, Lyndal Anderson, Anna DeFazio, Martin Kobel, Michael L. Friedlander, Susan J. Ramus

Summary: Clinical and gene expression data were analyzed to identify prognostic and diagnostic features of advanced-stage mucinous ovarian carcinoma (MOC) and differentiate it from gastrointestinal (GI) metastases. An infiltrative growth pattern was associated with poor prognosis, and high expression of THBS2 and TAGLN was linked to adverse prognosis in MOC. HER2 amplification or high mRNA expression was detected in some MOC cases, suggesting the potential of HER2-targeted therapy. MOC samples clustered with upper GI tumors, indicating similar biology and treatment strategies.

CLINICAL CANCER RESEARCH (2022)

Article Multidisciplinary Sciences

Interferon-& epsilon; is a tumour suppressor and restricts ovarian cancer

Zoe R. C. Marks, Nicole Campbell, Niamh Mangan, Cassandra S. Vandenberg, Linden S. Gearing, Antony Matthews, Jodee L. Gould, Michelle N. Tate, Georgie Wray-McCann, Le J. Ying, Sarah Rosli, Natasha Brockwell, Belinda Parker, San Lim, Maree Bilandzic, Elizabeth Christie, Andrew Stephens, Eveline de Geus, Matthew Wakefield, Gwo-Yaw Ho, Orla A. McNally, David D. L. Australian Ovarian Cancer Study, Iain A. McNeish, David D. L. L. Bowtell, Nicole M. de Weerd, Clare J. Scott, Nollaig Bourke, Paul Hertzog

Summary: High-grade serous ovarian cancers have low survival rates due to late presentation and chemoresistance. In this study, we investigate the tumor-suppressive activities of interferon-e (IFNe) in ovarian cancer models. We find that IFNe is constitutively expressed in the fallopian tube and lost during tumor development. IFNe directly acts on tumor cells and activates anti-tumor immunity. It prevents the accumulation and activation of suppressor cells and regulatory T cells. Our findings suggest that IFNe could be a potential therapeutic target for ovarian cancer.

NATURE (2023)

Review Oncology

Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer

Ana C. Veneziani, Clare Scott, Matthew J. Wakefield, Anna V. Tinker, Stephanie Lheureux

Summary: Poly (ADP-ribose) polymerase inhibitors (PARPis) have revolutionized the treatment of epithelial ovarian cancer, but resistance to PARPi has become a major concern. Ongoing studies aim to understand the mechanisms of resistance and explore potential therapeutic strategies to overcome this issue.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2023)

Article Endocrinology & Metabolism

Hemolytic uremic syndrome

A. Salpietro, V Sinatra, V Mottola, A. Ceravolo, V Chirico, L. Colavita, G. Ceravolo, E. Gitto, C. Cuppari, R. Chimenz

Summary: HUS is a thrombotic microangiopathy characterized by thrombocytopenia, non-immune microangiopathic hemolytic anemia, and acute kidney injury. It can be classified into typical and atypical types, with common pathogenetic features including damage of endothelial cells, intravascular hemolysis, coagulation abnormalities, and microthrombus formation.

JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS (2022)

Article Biochemistry & Molecular Biology

Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance

Rachel M. Hurley, Cordelia D. McGehee, Ksenija Nesic, Cristina Correia, Taylor M. Weiskittel, Rebecca L. Kelly, Annapoorna Venkatachalam, Xiaonan Hou, Nicholas M. Pathoulas, X. Wei Meng, Olga Kondrashova, Marc R. Radke, Paula A. Schneider, Karen S. Flatten, Kevin L. Peterson, Marc A. Becker, Ee Ming Wong, Melissa S. Southey, Alexander Dobrovic, Kevin K. Lin, Thomas C. Harding, Iain McNeish, Christian A. Ross, Jill M. Wagner, Matthew J. Wakefield, Clare L. Scott, Paul Haluska, Andrea E. Wahner Hendrickson, Larry M. Karnitz, Elizabeth M. Swisher, Hu Li, S. John Weroha, Scott H. Kaufmann

Summary: This study demonstrates that PARPi resistance can reverse RAD51C methylation and restore RAD51C expression, providing a model for investigating the relationship between PARPi and platinum sensitivity.

NAR CANCER (2021)

No Data Available